ArticleBiologics : targets & therapy2025

Dual Anti-HER2 Therapy Vs Trastuzumab Alone with Neoadjuvant Anthracycline and Taxane in HER2-Positive Early-Stage Breast Cancer: Real-World Insights.

Baha Sharaf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.